Literature DB >> 24294861

[Consensus on the management of lymphoma with HBV infection].

.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24294861     DOI： 10.3760/cma.j.issn.0253-2727.2013.11.019

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN： 0253-2727


× No keyword cloud information.
  8 in total

1.  [The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China(2022)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-05-14

2.  Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.

Authors:  Kai-Lin Chen; Jie Chen; Hui-Lan Rao; Ying Guo; Hui-Qiang Huang; Liang Zhang; Jian-Yong Shao; Tong-Yu Lin; Wen-Qi Jiang; De-Hui Zou; Li-Yang Hu; Michael Lucas Wirian; Qing-Qing Cai
Journal:  Chin J Cancer       Date:  2015-05-28

3.  The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.

Authors:  Qingqing Cai; Kailin Chen; Jie Chen; Shaoxu Wu; Qirong Geng; Huiqiang Huang; Tongyu Lin; Wenqi Jiang; Zhongjun Xia; Huaxin Duan; Huilan Rao; Mengfei Yao; Liyang Hu
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

4.  Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.

Authors:  Jianqiu Wu; Yongping Song; Liping Su; Li Xu; Tingchao Chen; Zhiyun Zhao; Mingzhi Zhang; Wei Li; Yu Hu; Xiaohong Zhang; Yuhuan Gao; Zuoxing Niu; Ru Feng; Wei Wang; Jiewen Peng; Xiaolin Li; Xuenong Ouyang; Changping Wu; Weijing Zhang; Yun Zeng; Zhen Xiao; Yingmin Liang; Yongzhi Zhuang; Jishi Wang; Zimin Sun; Hai Bai; Tongjian Cui; Jifeng Feng
Journal:  BMC Cancer       Date:  2016-07-26       Impact factor: 4.430

5.  [The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2018 edition)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14

6.  [Analysis of HBV, HCV and EBV infections in diffuse large B cell lymphoma].

Authors:  X J Wu; C G Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-09-14

7.  Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.

Authors:  Jian-Qiu Wu; Yong-Ping Song; Li-Ping Su; Ming-Zhi Zhang; Wei Li; Yu Hu; Xiao-Hong Zhang; Yu-Huan Gao; Zuo-Xing Niu; Ru Feng; Wei Wang; Jie-Wen Peng; Xiao-Lin Li; Xue-Nong Ouyang; Chang-Ping Wu; Wei-Jing Zhang; Yun Zeng; Zhen Xiao; Ying-Min Liang; Yong-Zhi Zhuang; Ji-Shi Wang; Zi-Min Sun; Hai Bai; Tong-Jian Cui; Ji-Feng Feng
Journal:  Chin Med J (Engl)       Date:  2018-08-05       Impact factor: 2.628

Review 8.  Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Yibo Wu; He Huang; Yi Luo
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.